Non-metastatic castration-resistant prostate cancer: management recommendations.

Autor: Alcaraz Asensio A; Servicio de Urología, Hospital Clinic de Barcelona, Barcelona, Spain. Electronic address: aalcaraz@clinic.cat., Alvarez Ossorio JL; Servicio de Urología, Hospital Puerta del Mar, Cadiz, Spain., Cozar Olmo JM; Servicio de Urología, Hospital Virgen de Las Nieves, Granada, Spain., Chantada Abal V; Servicio de Urología, Complejo Hospitalario Universitario A Coruña, A Coruña, Spain., Juarez Soto A; Servicio de Urología, Hospital de Jerez, Jerez de la Frontera, Jerez, Spain., Linares Espinos E; Servicio de Urología, Hospital Universitario La Paz, Madrid, Spain., Moreno Jimenez J; Servicio de Urología, Complejo Hospitalario de Jaén, Jaén, Spain., Muñoz Rodriguez J; Servicio de Urología, Hospital Parc Taulí, Sabadell, Barcelona, Spain., Perez Fentes D; Servicio de Urología, Hospital Clínico Universitario Santiago de Compostela, Santiago de Compostela, Spain., Plata Bello A; Servicio de Urología, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain., Rodrigo Aliaga M; Servicio de Urología, Hospital General Universitario Castellón, Castellón, Spain., Unda Urzaiz M; Servicio de Urología, Hospital Universitario de Basurto, Bilbao, Spain., Vilaseca A; Servicio de Urología, Hospital Clinic de Barcelona, Barcelona, Spain.
Jazyk: English; Spanish; Castilian
Zdroj: Actas urologicas espanolas [Actas Urol Esp (Engl Ed)] 2022 May; Vol. 46 (4), pp. 193-213. Date of Electronic Publication: 2022 Mar 16.
DOI: 10.1016/j.acuroe.2021.11.001
Abstrakt: Introduction and Objective: Survival and quality of life (QoL) of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) deteriorate significantly when they develop metastases. New generation antiandrogens (apalutamide, enzalutamide and darolutamide) can prolong metastasis-free survival (MFS) and overall survival (OS) in these patients, maintaining their QoL.
Material and Methods: After the performance of a systematic review of the literature, a scientific committee reached a consensus on simple and practical recommendations to consolidate and improve the management of patients with nmCRPC in urology consultations.
Results: Recommendations are made on the frequency of PSA determination and imaging tests in patients with nmCRPC. The importance of co-morbidities in patients with nmCRPC is also highlighted, and recommendations are also made on functional and QoL assessment that can be carried out during urology consultations. The efficacy, safety, and effects on QoL of new generation antiandrogens are reviewed.
Conclusions: To evaluate treatment of patients with nmCRPC, it is necessary to consider co-morbidities and QoL, in addition to age. New generation antiandrogens are a safe and effective treatment option for patients with nmCRPC. The recommendations of this review can be helpful in optimizing the management of nmCRPC patients in urology consultations.
(Copyright © 2021 AEU. Published by Elsevier España, S.L.U. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: